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responding to the standard of care: More questions than answersTo the Editor:
We read with interest the comment by Serfaty and
collaborators on our previous paper, and congratulate
them for the successful outcome of this interesting case.
We fully agree that our approach may have been inade-
quate and concur that, based on this case report and on
other recent data [1–3], the pharmacological correction
of the level of insulin resistance prior to retreatment with
antivirals should be more aggressive, and possibly pre-
cede the administration of the interferon-alpha/ribavirin
combination, until a HOMA score associated with a
higher rate of sustained virological response has been
reached [4,5].
It is noteworthy that the patient described by Ser-
faty and colleagues was infected by the genotype 3a
of HCV. In in vitro models [6], the mechanism of
virally-associated insulin resistance has been reported
to be HCV genotype-speciﬁc, the genotype 3a being
partly associated with the downregulation of peroxi-
some proliferator-activated receptor (PPAR)-c. Treat-
ment of transfected cells with a PPAR-c agonist
(rosiglitazone) partially reverted the suppression of
the insulin signaling associated with the expression
of the HCV core protein [6]. Thus, it is possible
that the insulin sensitizing therapy should be tailored
according to the infecting HCV genotype. In the IN-
SPIRED-HCV trial, only one patient was infected
with genotype 3a. This patient had extensive ﬁbrosis
and a mild steatosis aﬀecting 20% of hepatocytes,
but no overweight or arterial hypertension. Quite
oddly, upon retreatment, her HOMA-IR score
underwent a surge from 2.65 to 11, while serum
HCV RNA level remained unmodiﬁed. We fear that
this paradoxical increase may have been the conse-quence of a pharmacological interaction between
interferon-alpha and two additional drugs, i.e.
duloxetine and zopiclone, which have been occasion-
ally associated with glucose metabolism derange-
ments [6].
We remain convinced that correcting insulin resis-
tance is a rational option in chronic hepatitis C patients
failing to respond to combination therapy. However, the
modalities of this correction have to be fully explored.
The sequential administration of higher doses of insulin
sensitizers seems a reasonable approach, but the likely
genotype speciﬁcity of the mechanisms underlying the
insulin resistant state and the risk of pharmacological
interactions should both be taken in consideration be-
fore designing clinical trials. Finally, one should not for-
get that the most eﬀective way of correcting glucose
metabolism disturbances consists in lifestyle interven-
tions [7], such as diet modiﬁcations and increased phys-
ical activity, and that there is no excuse why chronic
hepatitis C patients should be spared such interventions.
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